Suscribirse

A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study - 02/09/11

Doi : 10.1016/S0002-9343(02)01236-6 
Simon Stewart, PhD a, 1, Carole L Hart, MA b, David J Hole, MSc c, John J.V McMurray, MD d,
a Division of Health Sciences at the University of South Australia (SS), Adelaide, Australia 
b Department of Public Health (CLH), University of Glasgow, Glasgow, United Kingdom 
c West of Scotland Cancer Surveillance Unit (DJH), University of Glasgow, Glasgow, United Kingdom 
d Clinical Research Initiative in Heart Failure (JJVM), University of Glasgow, Glasgow, United Kingdom 

*Requests for reprints should be addressed to John J. V. McMurray, MD, Department of Cardiology, University of Glasgow, Western Infirmary, Glasgow G11 6NT, United Kingdom

Abstract

Purpose

To describe the effect of atrial fibrillation on long-term morbidity and mortality.

Subjects and methods

The Renfrew/Paisley Study surveyed 7052 men and 8354 women aged 45–64 years between 1972 and 1976. All hospitalizations and deaths occurring during the subsequent 20 years were analyzed by the presence or absence of atrial fibrillation at baseline. Lone atrial fibrillation was defined in the absence of other cardiovascular signs or symptoms. Cox proportional hazards models were used to adjust for age and cardiovascular conditions.

Results

After 20 years, 42 (89%) of the 47 women with atrial fibrillation had a cardiovascular event (death or hospitalization), compared with 2276 (27%) of the 8307 women without this arrhythmia. Among men, 35 (66%) of 53 with atrial fibrillation had an event, compared with 3151 (45%) of 6999 without atrial fibrillation. In women, atrial fibrillation was an independent predictor of cardiovascular events (rate ratio [RR] = 3.0; 95% confidence interval [CI]: 2.1–4.2), fatal or nonfatal strokes (RR = 3.2; 95% CI: 1.0–5.0), and heart failure (RR = 3.4; 95% CI: 1.9–6.2). The rate ratios among men were 1.8 (95% CI: 1.3–2.5) for cardiovascular events, 2.5 (95% CI: 1.3–4.8) for strokes, and 3.4 (95% CI: 1.7–6.8) for heart failure. Atrial fibrillation was an independent predictor of all-cause mortality in women (RR = 2.2; 95% CI: 1.5–3.2) and men (RR = 1.5; 95% CI: 1.2–2.2). However, lone atrial fibrillation (which occurred in 15 subjects) was not associated with a statistically significant increase in either cardiovascular events (RR = 1.5; 95% CI: 0.6–3.6) or mortality (RR = 1.8; 95% CI: 0.9–3.8).

Conclusion

Atrial fibrillation is associated with an increased long-term risk of stroke, heart failure, and all-cause mortality, especially in women.

El texto completo de este artículo está disponible en PDF.

Keywords : Atrial fibrillation, Epidemiology, Prognosis, Morbidity, Heart failure, Stroke


Esquema


© 2002  Excerpta Medica Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 113 - N° 5

P. 359-364 - octobre 2002 Regresar al número
Artículo siguiente Artículo siguiente
  • A population-based study of mortality among patients with atrial fibrillation or flutter
  • Humberto Vidaillet, Juan F Granada, P.o-Huang Chyou, Karen Maassen, Mario Ortiz, Juan N Pulido, Param Sharma, Peter N Smith, John Hayes

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.